Literature DB >> 11096723

Primary Central Nervous System Tumors in Adults.

.   

Abstract

It is important that before treatment is initiated, the precise diagnosis of brain tumor has been made and fits with the clinical, radiographic, and histologic findings. With low-grade gliomas, maximal surgical resection should be attempted. We delay radiation therapy unless the patient has significant neurologic symptoms that could be alleviated by treatment. Patients with glioblastoma multiforme (GBM) and anaplastic astrocytoma should undergo maximum surgical resection, postoperative radiation therapy, and adjuvant chemotherapy with bischloroethylnitrosourea (BCNU) or intensive procarbazine, chloroethylcyclohexylnitrosourea (CCNU), and vincristine (PCV) therapy, respectively. Patients with anaplastic oligodendroglioma (AO) and mixed anaplastic oligodendroglioma-astrocytoma (AOA) should undergo maximal surgical resection, postoperative radiation therapy, and intensive adjuvant PCV therapy. Meningiomas are usually managed with surgery alone; radiation therapy is used if the meningioma is malignant or recurs. Tamoxifen or hydroxyurea may be useful for recurrent meningiomas. Patients with primary central nervous system (CNS) lymphoma undergo biopsy; surgical resection of the tumor is not necessary. We treat immunocompetent patients with multimethod therapy. Patients with AIDS and primary CNS lymphoma receive radiation alone. Because the prognosis for primary CNS lymphomas has not changed significantly in the past 20 years, patients with these tumors should be enrolled in clinical trials if possible. Novel approaches, such as targeting angiogenesis, using signal transduction or invasion, or employing genes affecting growth control, are being pursued.

Entities:  

Year:  1999        PMID: 11096723     DOI: 10.1007/s11940-996-0002-1

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  44 in total

1.  Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation.

Authors:  C Leighton; B Fisher; G Bauman; S Depiero; L Stitt; D MacDonald; G Cairncross
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

2.  Adjuvant combined modality therapy for malignant meningiomas.

Authors:  M C Chamberlain
Journal:  J Neurosurg       Date:  1996-05       Impact factor: 5.115

3.  Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994.

Authors:  T S Surawicz; B J McCarthy; V Kupelian; P J Jukich; J M Bruner; F G Davis
Journal:  Neuro Oncol       Date:  1999-01       Impact factor: 12.300

4.  Which glioblastoma multiforme patient will become a long-term survivor? A population-based study.

Authors:  J N Scott; N B Rewcastle; P M Brasher; D Fulton; J A MacKinnon; M Hamilton; J G Cairncross; P Forsyth
Journal:  Ann Neurol       Date:  1999-08       Impact factor: 10.422

5.  Salvage chemotherapy for oligodendroglioma.

Authors:  K Peterson; N Paleologos; P Forsyth; D R Macdonald; J G Cairncross
Journal:  J Neurosurg       Date:  1996-10       Impact factor: 5.115

Review 6.  Current management of primary central nervous system lymphoma.

Authors:  L M Deangelis
Journal:  Oncology (Williston Park)       Date:  1995-01       Impact factor: 2.990

7.  Increasing incidence of primary brain lymphoma in the US.

Authors:  N L Eby; S Grufferman; C M Flannelly; S C Schold; F S Vogel; P C Burger
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

8.  Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

Authors:  H A Fine; K B Dear; J S Loeffler; P M Black; G P Canellos
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

9.  A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.

Authors:  J W Goodwin; J Crowley; H J Eyre; B Stafford; K A Jaeckle; J J Townsend
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

10.  Petroclival meningiomas: surgical experience in 109 cases.

Authors:  W T Couldwell; T Fukushima; S L Giannotta; M H Weiss
Journal:  J Neurosurg       Date:  1996-01       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.